TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24051622

Group type: EXPERIMENTAL
Intervention: Sequential treatment (SEQ) with chemical nail avulsion, RV4104A ointment (40% urea), ciclopirox cream for 8 weeks, and ciclopirox nail lacquer for 25 weeks
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Sequential treatment (SEQ)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Amorolfine nail lacquer
Number of subjects: 142
Study: 20444308

Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg/kg) followed by lactate (10 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline followed by lactate
Number of subjects: 25
Study: 18314474

Group type: EXPERIMENTAL
Intervention: Tailored and targeted intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted-only intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Survey-only control group
Number of subjects: 0
Study: 17036484

Group type: EXPERIMENTAL
Intervention: Strong acupuncture intensity
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Moderate acupuncture intensity
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Weak acupuncture intensity
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral hypoglycemic drug (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acupuncture groups (strong, moderate, weak)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (oral hypoglycemic drug)
Number of subjects: 80
Study: 14743961

Group type: EXPERIMENTAL
Intervention: Pravastatin 80 mg/day for 8 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Normocholesterolaemic controls
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 62
Study: 10719694

Group type: EXPERIMENTAL
Intervention: Conventional Treatment Position (CTP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immobilisation System (IMS)
Number of subjects: 30
Study: 8732493

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic, euglycaemic clamp (1 mu kg‐1 min‐1, 5 mmol L‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic clamp
Number of subjects: 12
Study: 7904767

Group type: EXPERIMENTAL
Intervention: Broxaterol 400 micrograms q.i.d. for 4 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sodium chromoglycate 10 mg q.i.d. for 4 weeks (control)
Number of subjects: 48
Study: 3554492

Group type: EXPERIMENTAL
Intervention: Incision followed by fistulotomy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Incision only
Number of subjects: 38
Study: 29633646

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 27440671

Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS (1.5 mg/ml; total dose 4.2 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: ABG (autogenous bone graft)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS
Number of subjects: 24

Group type: COMPARATOR
Intervention: ABG
Number of subjects: 24
Study: 25825539

Group type: EXPERIMENTAL
Intervention: Provider + RD (Group 3) - delivered 4 MI sessions from providers plus 6 MI sessions from a registered dietitian.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Provider only (Group 2) - delivered 4 MI counseling sessions to parents over 2 years.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care (Group 1) - measured BMI percentile at baseline and 1- and 2-year follow-up.
Number of subjects: 42
Study: 23512651

Group type: EXPERIMENTAL
Intervention: Postcard reminders
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Mobile-phone text message reminders
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Telephone call reminders
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Patient satisfaction score increase
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: High patient satisfaction with reminders
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: General feelings about reminders
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Agreement on reminders enhancing intention to revisit
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Desire for continued reminders
Number of subjects: 389
Study: 22105509

Group type: EXPERIMENTAL
Intervention: ketorolac 0.45%
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: bromfenac 0.09%
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: nepafenac 0.1%
Number of subjects: 121
Study: 19255911

Group type: EXPERIMENTAL
Intervention: Verbalisation during task performance
Number of subjects: 22

Group type: COMPARATOR
Intervention: Silence during task performance
Number of subjects: 22
Study: 16217841

Group type: EXPERIMENTAL
Intervention: Dichotomization of continuous predictor variables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data-derived 'optimal' cutpoint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical analysis without dichotomization
Number of subjects: 0
Study: 12715124

Group type: EXPERIMENTAL
Intervention: BTAstat test
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: NMP 22 test
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Immunocytology with 486p3/12
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Immunocytology with Lewis X
Number of subjects: 115
Study: 10687882

Group type: EXPERIMENTAL
Intervention: E2 Matrix 0.10 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: E2 Matrix 0.05 mg
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 9377886

Group type: EXPERIMENTAL
Intervention: Hot water (HW) circuit with a 2‐day circuit change (n = 41)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Bacterial‐viral filtering HME with a 2‐day circuit change (n = 42)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Bacterial‐viral filtering HME with a 4‐day circuit change (n = 33)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Bacterial‐viral filtering HME (2-day change)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Bacterial‐viral filtering HME (4-day change)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: HME use
Number of subjects: 116

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: HME
Number of subjects: 116
Study: 8440761

Group type: EXPERIMENTAL
Intervention: Ethanol (25 mL in 150 mL of grapefruit juice)
Number of subjects: 4
Study: 3532535

Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy with diethylstilbestrol
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy with tamoxifen
Number of subjects: 118

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 118
Study: 28632529

Group type: EXPERIMENTAL
Intervention: High PEEP (12 cm H2O)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low PEEP (0-2 cm H2O)
Number of subjects: 36
Study: 29939700

Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip (PFT) endotracheal tube
Number of subjects: 100

Group type: COMPARATOR
Intervention: Preformed Nasal (PNT) tube
Number of subjects: 100
Study: 25380842

Group type: EXPERIMENTAL
Intervention: Endoscopic sequential treatment (Group A: local chemotherapeutic drug injection with ordinary metal stent implantation)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Endoscopic sequential treatment (Group B: local chemotherapeutic drug injection with iodine‐125 particle implantation)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Endoscopic sequential treatment (Group C: radiofrequency therapy with ordinary metal stent)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Traditional treatment (Group D: local chemotherapeutic drug injection)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Traditional treatment (Group E: RF therapy)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Traditional treatment (Group F: common metal stent implantation)
Number of subjects: 240
Study: 22008715

Group type: EXPERIMENTAL
Intervention: Implants with SLA surface
Number of subjects: 24
Study: 19936863

Group type: EXPERIMENTAL
Intervention: CTP (Computed Tomography Perfusion)
Number of subjects: 47

Group type: COMPARATOR
Intervention: SPECT-MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)
Number of subjects: 47
Study: 18692203

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 35

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 35
Study: 15784070

Group type: EXPERIMENTAL
Intervention: Smoking-related stimuli (denicotinized cigarettes)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of nicotine and smoking-related stimuli
Number of subjects: 32
Study: 12792123

Group type: EXPERIMENTAL
Intervention: Antidepressant medications
Number of subjects: 0
Study: 10590363

Group type: EXPERIMENTAL
Intervention: cisplatin-CDE (PCDE)
Number of subjects: 457

Group type: COMPARATOR
Intervention: CDE
Number of subjects: 457
Study: 8687199

Group type: EXPERIMENTAL
Intervention: Lazabemide 25 mg/day
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Lazabemide 50 mg/day
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Lazabemide 100 mg/day
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Lazabemide 200 mg/day
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 1531994

Group type: EXPERIMENTAL
Intervention: Budesonide, 1.6 mg daily for 3 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prednisone, 40 mg daily for 8 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4072589

Group type: EXPERIMENTAL
Intervention: N2O and oxygen
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: N2O, oxygen, and 0.25% halothane
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: N2O, oxygen, and 0.5% halothane
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: N2O, oxygen, and 0.5% enflurane
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: N2O, oxygen, and 1% enflurane
Number of subjects: 81

Group type: COMPARATOR
Intervention: N2O alone
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: N2O, oxygen, and halogenated agents
Number of subjects: 81
Study: 31623675

Group type: EXPERIMENTAL
Intervention: Oral vitamin C supplementation (500 mg daily during the last 2 cycles)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29498347

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation with pre-cooling
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pre-cooling
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 26645413

Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening
Number of subjects: 4055
Study: 24362951

Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) + Exemestane (EXE) (10 mg/day + 25 mg/day)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo (PBO) + Exemestane (EXE) (placebo + 25 mg/day)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) + Exemestane (EXE)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo (PBO) + Exemestane (EXE)
Number of subjects: 137
Study: 22863207

Group type: EXPERIMENTAL
Intervention: Usual care with moderate intensity aerobic exercise (12-week walking program at 60-75% HRmax)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Usual care with moderate intensity aerobic exercise
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care (sedentary)
Number of subjects: 19
Study: 20211040

Group type: EXPERIMENTAL
Intervention: Multivitamins (vitamins B-complex, C and E)
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Maternal multivitamin supplements
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Vitamin A plus beta-carotene
Number of subjects: 959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959
Study: 18575008

Group type: EXPERIMENTAL
Intervention: Nebulized bacitracin/colimycin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nasal endoscopic findings
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: SF-36 questionnaire
Number of subjects: 14
Study: 15831584

Group type: EXPERIMENTAL
Intervention: HIV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12356611

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine combined with interferon alfa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bufotoxin combined with interferon alfa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kurorinone
Number of subjects: 0
Study: 10613092

Group type: EXPERIMENTAL
Intervention: BiliBed
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 22
Study: 8540719

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg daily for 6 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg every 8 h for 5 days plus omeprazole)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clarithromycin with omeprazole
Number of subjects: 20
Study: 1789861

Group type: EXPERIMENTAL
Intervention: Diagnostic test with unknown accuracy parameters
Number of subjects: 0
Study: 6848681

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 31669837

Group type: EXPERIMENTAL
Intervention: Saffron (60 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sertraline (100 mg/day)
Number of subjects: 50
Study: 29505140

Group type: EXPERIMENTAL
Intervention: PE-formula
Number of subjects: 50

Group type: COMPARATOR
Intervention: S-formula
Number of subjects: 50
Study: 26387973

Group type: EXPERIMENTAL
Intervention: 5% minoxidil topical foam (5% MTF)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo topical foam (plaTF) until week 24, followed by 5% MTF until week 104
Number of subjects: 45
Study: 25000669

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice
Number of subjects: 116

Group type: COMPARATOR
Intervention: Marketed sodium fluoride dentifrice (negative control)
Number of subjects: 116
Study: 23052313

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (SXT) on Mueller-Hinton agar (MHA) with defibrinated horse blood and 20 mg/liter β‐NAD (MHF)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (SXT) on MHA with sheep blood (MHS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (SXT) on MHA alone (MHA)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (SXT) on MHA with horse blood (MHBA)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (SXT) on MHA with lysed horse blood (MHLHBA)
Number of subjects: 200
Study: 20435188

Group type: EXPERIMENTAL
Intervention: Perindopril + CCB
Number of subjects: 2122
Study: 17420182

Group type: EXPERIMENTAL
Intervention: Male latex condom
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Female polyurethane condom
Number of subjects: 108

Group type: COMPARATOR
Intervention: Mechanical problems (both condoms)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Correct use with no problems (both condoms)
Number of subjects: 108
Study: 16379508

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 21
Study: 11927527

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 898
Study: 9797517

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg.kg‐1 with spontaneous recovery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg.kg‐1 with neostigmine at 10% recovery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg.kg‐1 with neostigmine at 25% recovery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg.kg‐1 with spontaneous recovery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg.kg‐1 with neostigmine at 10% recovery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg.kg‐1 with neostigmine at 25% recovery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1 with spontaneous recovery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1 with neostigmine at 10% recovery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1 with neostigmine at 25% recovery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 0
Study: 8583056

Group type: EXPERIMENTAL
Intervention: Five-rung grip test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid exchange grip test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model for categorizing patients
Number of subjects: 0
Study: 2663868

Group type: EXPERIMENTAL
Intervention: Corrective orthopaedic shoes
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Helfet heel-cup
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Custom-molded plastic insert
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study: 241599

Group type: EXPERIMENTAL
Intervention: Alclofenac 1 g t.d.s.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 11
Study: 31926224

Group type: EXPERIMENTAL
Intervention: Brief CBT (5 sessions, 5.5 hours)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Standard CBT (10 sessions, 15 hours)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Brief CBT
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Standard CBT
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Both brief and standard CBT
Number of subjects: 313

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 313
Study: 30715779

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powders (MNPs)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Nurturant home environment
Number of subjects: 829

Group type: COMPARATOR
Intervention: Inflammation presence
Number of subjects: 829
Study: 28493923

Group type: EXPERIMENTAL
Intervention: 10 minute deep breathing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 26181338

Group type: EXPERIMENTAL
Intervention: Whole-body point-of-care ultrasound curriculum (Focused periOperative Risk Evaluation Sonography Involving Gastroabdominal Hemodynamic and Transthoracic ultrasound)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pathology assessment training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Clinical examinations post-training
Number of subjects: 42
Study: 23169695

Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GH+Testosterone
Number of subjects: 12
Study: 21763198

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 19166395

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 426

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 426
Study: 17114560

Group type: EXPERIMENTAL
Intervention: Midazolam syrup (0.5 mg/kg)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 15233550

Group type: EXPERIMENTAL
Intervention: 30 Hz whole body vibration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (absence of vibration)
Number of subjects: 10
Study: 11764398

Group type: EXPERIMENTAL
Intervention: 188Re irradiation using an angioplasty balloon
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 26
Study: 9235377

Group type: EXPERIMENTAL
Intervention: Ozone-containing solutions
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58

Group type: COMPARATOR
Intervention: Experimental group
Number of subjects: 58
Study: 8234438

Group type: EXPERIMENTAL
Intervention: Bulk laxative plus senna (Agiolax) daily doses 14.8 g
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lactulose (Levolac) daily doses 20.1 g
Number of subjects: 30
Study: 3303178

Group type: EXPERIMENTAL
Intervention: 1% mepivacaine (40 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1% prilocaine (40 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 29300876

Group type: EXPERIMENTAL
Intervention: CYD‐TDV (Dengvaxia)
Number of subjects: 31000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31000

Group type: EXPERIMENTAL
Intervention: Probable dengue definition
Number of subjects: 31000
Study: 27282457

Group type: EXPERIMENTAL
Intervention: High-load resistance training (80% 1RM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-load resistance training (30% 1RM)
Number of subjects: 15
Study: 23559323

Group type: EXPERIMENTAL
Intervention: Postoperative systemic steroids (100 mg prednisolone per day for 5 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 28
Study: 23425733

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Phenytoin (PHE)
Number of subjects: 813
Study: 20845213

Group type: EXPERIMENTAL
Intervention: Instep kick
Number of subjects: 10

Group type: COMPARATOR
Intervention: Outstep kick
Number of subjects: 10
Study: 19047509

Group type: EXPERIMENTAL
Intervention: Mediated learning experience articulated with concept mapping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional methodology (control group)
Number of subjects: 0
Study: 15572391

Group type: EXPERIMENTAL
Intervention: Knee pain induced by injection of hypertonic saline into the infrapatellar fat pad
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control condition (no knee pain)
Number of subjects: 12